AIRR
Unlocking a new class of reperfusion-protective medicines to prevent acute kidney injury and improve outcomes in heart attacks and organ transplants.
About Us
AIRR (Aiding Ischemic Reperfusion Recovery) is a portfolio company of Fannin based in Houston, Texas. AIRR is dedicated to creating first-in-class reperfusion-protective medicines that address the critical unmet needs associated with ischemia-reperfusion injury across multiple therapeutic areas.
Our lead candidate, DMX-5804, is designed to modulate key stress-response pathways activated during reperfusion, offering a targeted approach to reduce tissue damage and improve organ recovery.
In all three established use cases, DMX-5804 is designed to work alongside current standards of care and validated clinical procedures, enhancing outcomes by targeting the causes of reperfusion injury that current interventions cannot address
By addressing a long-standing gap in reperfusion medicine, there is also potential and optionality for future expansion into additional high-burden, reperfusion-mediated diseases.
AIRR aims to deliver meaningful protection and improvements in patient survival, recovery, and long-term, post-procedure organ function.
Innovation
AIRR is innovative because we are targeting the common biochemical mechanism underlying reperfusion injury across the heart, kidneys, and most transplanted organs. This creates:
A multi-indication opportunity
Cross-organ biological consistency
A scalable, platform-like therapeutic strategy
We are developing a new therapeutic category: reperfusion-protective medicine.
Most innovations in MI, transplant, and AKI require massive workflow changes (devices, complex biologics, timing challenges). AIRR’s approach is designed to layer onto existing SOC procedures. This ease of integration dramatically improves real-world adoption potential.
Current standard of care addresses restoring blood flow (MI), preventing immune rejection (transplant), or stabilizing renal function (AKI), but none protect against the sudden oxidative and inflammatory surge triggered during reperfusion. AIRR directly targets this gap.
Because reperfusion injury drives downstream complications, AIRR’s approach has potential to improve both acute outcomes and long-term organ function.